Table 1.
Patients’ characteristics. Qualitative values are shown in numbers and percentages of patients. Quantitative values are shown as mean ± standard deviation (minimum, maximum).
| Parameter | |
|---|---|
| Sex (M/F) | 11/13 |
| Age at baseline (y) | 34.0 ± 12.5 (19,55) |
| BMI at baseline (kg/m2) | 23.9 ± 6.9 (16.3, 39.5) |
| Duration of disease at baseline (y) | 10.3 ± 9.0 (1,39) |
| Disease location | |
| Ileal, n (%) | 16 (67 %) |
| Ileocolic, n (%) | 8 (33 %) |
| Anti-TNF type | |
| Adalimumab (Humira), n (%) | 11 (46) |
| Infliximab (Remicade), n (%) | 11 (46) |
| Golimumab (Simponi), n (%) | 1 (4) |
| Certolizumab (Cimzia), n (%) | 1 (4) |
| Concomitant treatments | |
| 5-Aminosalcylate, n (%) | 0 (0) |
| Steroids, n (%) | 1 (4) |
| Immunosuppressants (6-Mercaptopurine, Methotrexate, Azathioprine) | 14 (54) |
| CRP baseline (mg/l) | 33.6 ± 42.1 (0.5,155.3) |
| CRP follow-up (mg/l) | 27.1 ± 48.6 (0.6, 164.7) |
| Smoking status at baseline (Y/N) | 2/22 |